PDF Version

PDF 版本

Therapeutic effects were sustained off treatment, with persistent reduction in HbA1c and improvement in beta-cell function 3 months after last dose, suggesting disease-modifying potential of icovamenib

治疗效果在停药后仍然持续，HbA1c持续降低，β细胞功能在最后一剂后3个月得到改善，这表明伊可伐美尼具有改变疾病进程的潜力。

Strong correlation between C-peptide increase and HbA1c reduction (r = -0.73, p<0.0001) across all dosing groups (n=23) support the proposed mechanism of beta cell restoration

所有剂量组（n=23）中，C肽增加与HbA1c降低之间存在显著相关性（r = -0.73，p<0.0001），这支持了所提出的β细胞恢复机制。

Best response observed in prespecified, beta-cell deficient patients on one or more antihyperglycemic agents at baseline, achieving a statistically significant placebo-adjusted mean reduction in HbA1c of 1.47% at Week 26 (p=0.022), after only 12 weeks of 100 mg once daily icovamenib

预先指定的、基线时使用一种或多种抗高血糖药物的β细胞缺乏患者中观察到最佳反应，在每日一次100 mg伊科伐美尼治疗仅12周后，第26周时HbA1c的安慰剂校正平均降幅达到统计学显著水平，为1.47%（p=0.022）。

Preclinical in vivo experiments indicated that icovamenib enhanced the responsiveness of human islets to GLP-1-based medicines, consistent with the increase in expression levels (transcript and protein) of both the GLP-1 receptor and intracellular insulin

临床前体内实验表明，艾考那肽增强了人胰岛对基于GLP-1的药物的反应性，这与GLP-1受体和细胞内胰岛素的表达水平（转录和蛋白）增加一致。

Severe Insulin Deficient Diabetes represents an underserved patient population within type 2 diabetes and is estimated to be over 100 million people worldwide.

严重胰岛素缺乏型糖尿病代表了2型糖尿病中未得到充分服务的患者群体，据估计全球有超过1亿人受其影响。

REDWOOD CITY, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the presentation of preclinical and clinical data from studies assessing icovamenib at the

加利福尼亚州红木城，2025年3月24日（环球新闻社）-- Biomea Fusion, Inc.（“Biomea”）（纳斯达克股票代码：BMEA），一家临床阶段的糖尿病和肥胖症药物公司，今天宣布了在评估icovamenib的研究中呈现的临床前和临床数据。

Advanced Technologies & Treatments for Diabetes

糖尿病的先进技术和治疗手段

(ATTD) 2025 Conference

（ATTD）2025年会议

in Amsterdam, The Netherlands. The new findings support icovamenib’s potential as a first-in-class, disease-modifying therapy by targeting beta-cell restoration, enhancing insulin secretion, and sustaining glycemic improvements beyond icovamenib’s treatment period.

在荷兰阿姆斯特丹。新发现支持了伊可伐单抗通过靶向β细胞恢复、增强胰岛素分泌以及在治疗期结束后持续改善血糖水平，作为首创新疗法的潜力。

“At ATTD, we presented data on icovamenib’s ability to drive a significant increase in C-peptide production in patients who need it most, demonstrating a durable effect that lasted well beyond the treatment period. This is an exciting moment for icovamenib, but most importantly an exciting moment for patients who are in need of an alternative mechanism of action for their diabetes.

“在ATTD会议上，我们展示了伊科伐美尼（icovamenib）在最需要治疗的患者中显著提升C肽生成的能力，其效果持久，远远超出治疗期。这对伊科伐美尼而言是激动人心的时刻，但更重要的是，对那些需要新型作用机制来治疗糖尿病的患者来说，这是一个令人兴奋的时刻。

This data validates the topline analysis reported last December, highlighting the impactful responses seen in those with poor beta cell function at baseline. With icovamenib, we look to increase the fundamental capability of our patients, enabling them to produce more insulin on their own and take back control of their diabetes.

这些数据验证了去年十二月报告的顶线分析，突显了在基线时β细胞功能较差的患者中观察到的显著反应。通过伊科伐米尼，我们希望提升患者的基本能力，使他们能够自行产生更多的胰岛素，重新掌控自己的糖尿病。

We look forward to providing further updates with this study as we continue to uncover the broad potential of icovamenib in type 2 diabetes,” said Thomas Butler, Chief Executive Officer and Chairman of Biomea Fusion..

“我们期待随着继续发掘 icovamenib 在 2 型糖尿病中的广泛潜力，为这项研究提供进一步的更新，”Biomea Fusion 首席执行官兼董事长托马斯·巴特勒表示。

Icovamenib, an investigational, covalent menin inhibitor, is being evaluated for its ability to restore pancreatic beta-cell mass and function, which are key drivers of disease progression in insulin-deficient diabetes. The presentations provided comprehensive insights into icovamenib’s mechanism of action, long-term clinical activity, biomarker responses, safety profile, and potential as a combination therapy with GLP-1-based medicines..

Icovamenib是一种在研的共价menin抑制剂，正被评估其恢复胰腺β细胞质量和功能的能力，这是胰岛素缺乏型糖尿病疾病进展的关键驱动因素。报告全面介绍了icovamenib的作用机制、长期临床活性、生物标志物反应、安全性特征，以及其与GLP-1类药物联用的潜力。

“These findings reinforce the potential role of icovamenib in improving beta-cell function even after treatment cessation. The significant increase in C-peptide levels observed in icovamenib-treated patients more than 3 months after stopping therapy supports the proposed mechanism of action, the restoration of beta cell mass and function,” said Juan Pablo Frías, MD, Chief Medical Officer of Biomea Fusion.

“这些研究结果进一步证实了伊可伐美尼在改善β细胞功能方面的潜在作用，即使在治疗停止后也是如此。在停止治疗三个多月后，使用伊可伐美尼治疗的患者体内C肽水平显著增加，这支持了其作用机制，即恢复β细胞质量和功能，”Biomea Fusion首席医疗官胡安·巴勃罗·弗里亚斯 (Juan Pablo Frías) 医学博士说道。

“Additionally, we have observed benefits consistent with a potential synergy between icovamenib and GLP-1-based medicines, highlighting icovamenib’s potential to complement existing and broadly used therapies. We are eager to continue advancing this novel approach and are working towards bringing a first-in-class, potentially disease-modifying therapy to patients.

“此外，我们观察到伊科伐美尼与基于GLP-1的药物之间可能存在协同效应，这突显了伊科伐美尼作为现有广泛使用疗法补充的潜力。我们渴望继续推进这一新颖的方法，并致力于为患者带来首个可能改变疾病进程的疗法。”

The ability to restore beta-cell function, thereby improving insulin production and secretion, could be a game-changer for patients with severe insulin deficiency, a population that has long been underserved by current treatment options.”.

恢复β细胞功能从而改善胰岛素生成和分泌的能力，可能成为严重胰岛素缺乏患者的一个改变局面的突破，这一群体长期以来未被当前治疗手段充分顾及。

ATTD 2025 Conference Highlights:

ATTD 2025会议亮点：

First Large-Scale Analysis of C-Peptide Response:

首次大规模C肽反应分析：

The data represents the first large-scale assessment of C-peptide levels in icovamenib-treated patients, providing robust evidence supporting its proposed mechanism of action. C-peptide, a key biomarker of endogenous insulin production, demonstrated significant increases, indicating improved pancreatic beta-cell function over 3 months after the final dose of icovamenib..

数据显示了对接受Icovamenib治疗的患者进行的首次大规模C肽水平评估，为该药物提出的机制提供了有力证据。C肽是内源性胰岛素生产的关键生物标志物，其显著增加表明在Icovamenib最后剂量后的3个月内胰腺β细胞功能得到了改善。

OGTT-Based Beta-Cell Function Assessment:

基于OGTT的β细胞功能评估：

An oral glucose tolerance test (OGTT) was conducted at baseline and six timepoints over 26 weeks, providing a detailed evaluation of beta-cell insulin secretory capacity. This test is considered a robust and well-validated method of assessing beta cell insulin secretory capacity via assessment of the C-peptide index, the ratio of plasma C-peptide per unit of glucose.

在基线和26周内的六个时间点进行了口服葡萄糖耐量试验（OGTT），详细评估了β细胞的胰岛素分泌能力。该测试通过评估C肽指数（每单位葡萄糖的血浆C肽比值）来衡量β细胞胰岛素分泌能力，被认为是一种可靠且经过充分验证的方法。

This offers critical insights into icovamenib’s impact on pancreatic beta-cell function..

这为 icovamenib 对胰腺 β 细胞功能的影响提供了重要的见解。

C-Peptide Increases in Insulin-Deficient Subgroups:

C肽在胰岛素缺乏的亚组中增加：

Patients with insulin deficient diabetes (n=45) experienced a mean increase in C-peptide index levels. In particular the severe insulin-deficient diabetes patients who received icovamenib (n=23) experienced the largest mean increase in C-peptide index levels by Week 26 (53% mean increase from baseline)..

胰岛素缺乏型糖尿病患者（n=45）的C肽指数水平平均上升。特别是那些接受Icovamenib治疗的严重胰岛素缺乏型糖尿病患者（n=23），在第26周时C肽指数水平平均上升幅度最大（较基线上升53%）。

Long-Term Beta-Cell Restoration Potential:

长期β细胞恢复潜力：

Insulin deficient patients who received icovamenib (n=45) demonstrated a persistent increase in C-peptide levels beyond the active treatment period, over 3 months after the final dose of icovamenib, suggesting a durable effect on insulin secretion and reinforcing our belief in icovamenib’s potential to drive long-term improvements in beta-cell function..

接受伊可伐明治疗的胰岛素缺乏患者（n=45）在活性治疗期结束后，C肽水平持续增加，且在伊可伐明最后一剂后超过3个月仍然如此，这表明其对胰岛素分泌具有持久影响，并进一步强化了我们对伊可伐明推动β细胞功能长期改善潜力的信心。

Strong Correlation between C-peptide and HbA1c:

C肽与HbA1c之间存在强相关性：

An analysis of the severe insulin-deficient diabetes subgroup of participants (n=23) who were uncontrolled on at least one prior antihyperglycemic therapy revealed a strong correlation between changes in C-peptide index and HbA1c at Week 26 (r=-0.73). The strong correlation between the improvement in HbA1c and the increase in C-peptide index, 14 weeks after cessation of icovamenib therapy, supports the proposed mechanism of action of icovamenib, a durable improvement in beta-cell function.

对至少使用过一种先前抗高血糖疗法但未得到控制的严重胰岛素缺乏型糖尿病亚组参与者（n=23）的分析显示，第26周时C肽指数的变化与HbA1c之间存在强相关性（r=-0.73）。在停止伊可伐米尼治疗14周后，HbA1c改善与C肽指数增加之间的强相关性支持了伊可伐米尼的作用机制，即β细胞功能的持久改善。

These data suggests that icovamenib fundamentally impacted the disease, potentially restoring the patient’s ability to produce more insulin, after a short treatment period..

这些数据表明，伊科伐单抗从根本上影响了疾病，可能在短时间内恢复了患者产生胰岛素的能力。

Precision Medicine Potential:

精准医学潜力：

Analysis across different diabetes subtypes demonstrated that icovamenib preferentially increased insulin secretion in insulin-deficient patients, highlighting its potential as a targeted therapy for individuals with severe insulin deficiency, a population with limited treatment options and the highest risk profile..

对不同糖尿病亚型的分析表明，Icovamenib优先增加胰岛素缺乏患者的胰岛素分泌，突显了其作为严重胰岛素缺乏症患者靶向治疗的潜力，这一人群治疗选择有限且风险最高。

Enhanced Impact of GLP-1 based Therapeutic Agents with Icovamenib Combination:

GLP-1基础治疗药物与Icovamenib联合使用的增强效果：

Icovamenib enhanced responsiveness of human islets to the GLP-1-based medicines, semaglutide and tirzepatide. Enhancement in beta-cell function was correlated with an increase in the expression levels of the GLP-1 receptor as well as intracellular insulin – both transcript and protein levels were increased.

Icovamenib增强了人胰岛对基于GLP-1的药物司美鲁肽和替西帕肽的反应性。β细胞功能的增强与GLP-1受体表达水平以及细胞内胰岛素的增加相关，其转录和蛋白水平均有所提升。

These effects induced by icovamenib may allow lower doses of GLP-1-based medicines to achieve glycemic targets, potentially improving tolerability of these agents..

这些由伊考瓦美尼布诱导的效应可能允许更低剂量的基于GLP-1的药物实现血糖目标，可能提高这些药物的耐受性。

ATTD 2025 Presentations:

ATTD 2025 演讲：

All abstracts will be published in the peer-reviewed Journal of Diabetes Technology & Therapeutics. All presentations and the symposium slides are also available on Biomea Fusion’s Investor Relations Page under the Events section

所有摘要都将发布在经过同行评审的《糖尿病技术与治疗学杂志》上。所有的演讲和研讨会幻灯片也可以在Biomea Fusion的投资者关系页面的“活动”部分找到。

https://investors.biomeafusion.com/news-events

https://investors.biomeafusion.com/news-events

.

。

Global Experts across the Diabetes Field have also Recognized the Significance of these Findings:

糖尿病领域的全球专家也认识到了这些发现的重要性：

“Icovamenib's recent data has shown an impressive restoration of beta cell function as demonstrated by significant elevations in C-peptide even after the treatment period ended. This data validates the proposed mechanism of action of this menin inhibitor as a disease modifying agent and helps address the poor adherence and persistence commonly seen in type 2 diabetes.”.

“Icovamenib的最新数据表明，即使在治疗期结束后，C肽显著升高，β细胞功能得到令人印象深刻的恢复。该数据验证了这种menin抑制剂作为疾病修饰剂的拟议作用机制，并有助于解决2型糖尿病患者常见的依从性差和持久性不足的问题。”

Steve Edelman, M.D., Endocrinologist, Professor of Medicine UCSD / VA San Diego

史蒂夫·埃德尔曼，医学博士，内分泌学家，加州大学圣地亚哥分校/圣地亚哥退伍军人事务部医学教授

.

。

“We do not have an agent today that addresses one of the root causes of diabetes – beta cell dysfunction – icovamenib, if approved, would be the first. Patients in the COVALENT-111 trial have achieved lasting benefits without continuous chronic dosing, suggesting that icovamenib may be disease-modifying.

“我们目前没有一种药物能够解决糖尿病的根源之一——β细胞功能障碍——如果获得批准，Icovamenib 将是第一个。参与 COVALENT-111 试验的患者在无需持续长期用药的情况下获得了持久的益处，这表明 Icovamenib 可能具有疾病修饰作用。

I am very impressed.”.

我对此印象深刻。

Alice Cheng, M.D., Endocrinologist, Associate Professor of Medicine, University of Toronto.

郑爱丽丝，医学博士，内分泌学家，多伦多大学医学副教授。

“The C-peptide data which was presented during ATTD is a meaningful update, as we now have insight into why insulin-deficient patients may respond better to icovamenib treatment. The potential to restore endogenous insulin production capacity is an exciting development in the treatment of type 2 diabetes.”.

“在ATTD期间展示的C肽数据是一项有意义的更新，因为我们现在了解到为什么胰岛素缺乏患者可能对伊柯瓦美尼治疗反应更佳。恢复内源性胰岛素生产能力的潜力是2型糖尿病治疗中令人振奋的进展。”

Jeremy Pettus, M.D., Endocrinologist, Professor of Medicine UCSD.

杰里米·佩特鲁斯，医学博士，内分泌学家，加州大学圣地亚哥分校医学教授。

“Icovamenib is a very interesting molecule that acts quite differently than anything I have seen before. We are observing glucose controlled and beta cell-specific proliferation and an increase in stimulated C-peptide secretion leading to patient benefits that continued after the icovamenib dosage ended.

“伊可伐米尼是一种非常有趣的分子，其作用方式与我之前见过的任何药物都大不相同。我们观察到葡萄糖控制和β细胞特异性增殖，并且刺激C肽分泌增加，给患者带来了益处，这种益处在伊可伐米尼剂量结束后仍然持续。”

I am very excited to further explore the many opportunities that icovamenib driven inhibition of menin will provide to patients.”.

我非常兴奋能够进一步探索 icovamenib 驱动的 menin 抑制将为患者提供的众多机会。

Rohit N. Kulkarni, M.D., Ph.D., Professor of Medicine at Harvard Medical School.

罗希特·N·库尔卡尼（Rohit N. Kulkarni），医学博士、哲学博士，哈佛医学院医学教授。

About Menin’s Role in Diabetes

关于Menin在糖尿病中的作用

Loss of functional beta-cell mass and function is a core component of the natural history in both types of diabetes – type 1 diabetes (“T1D”) (mediated by autoimmune dysfunction) and type 2 diabetes (“T2D”) (mediated by metabolic dysfunction). Beta cells are found in the pancreas and are responsible for the synthesis and secretion of insulin.

功能性β细胞团和功能的丧失是两种类型糖尿病自然病史的核心组成部分——1型糖尿病（“T1D”）（由自身免疫功能障碍介导）和2型糖尿病（“T2D”）（由代谢功能障碍介导）。β细胞存在于胰腺中，负责胰岛素的合成与分泌。

Insulin is a hormone that helps the body use glucose for energy and helps control blood glucose levels. In patients with diabetes, beta-cell mass and function have been observed to be diminished, leading to insufficient insulin secretion and hyperglycemia. Menin is thought to act as a brake on beta-ell turnover and growth, supporting the notion that inhibition of menin could lead to the regeneration of normal, healthy beta cells.

胰岛素是一种帮助身体利用葡萄糖获取能量并帮助控制血糖水平的激素。在糖尿病患者中，观察到β细胞质量和功能下降，导致胰岛素分泌不足和高血糖。Menin被认为是对β细胞更新和生长的一种抑制因素，支持了抑制menin可能促进正常、健康的β细胞再生的观点。

Based on these and other scientific findings, Biomea is exploring the potential for icovamenib-mediated menin inhibition as a viable therapeutic approach to potentially halt or reverse progression of T2D..

基于这些和其他科学发现，Biomea 正在探索 icovamenib 介导的 menin 抑制作为潜在治疗途径的可行性，以可能阻止或逆转 2 型糖尿病 (T2D) 的进展。

About Type 2 Diabetes

关于2型糖尿病

Diabetes is considered a chronic health condition that affects how the body turns food into energy and results in excessive glucose in the bloodstream. Over time, this can cause serious health problems and damage vital organs. Most people with diabetes have a shorter life expectancy than people without this disease.

糖尿病被认为是一种慢性健康状况，影响身体将食物转化为能量的方式，并导致血糖过高。随着时间的推移，这可能会引起严重的健康问题并损害重要器官。大多数糖尿病患者的预期寿命比没有这种疾病的人要短。

The Centers for Disease Control and Prevention estimates about two in five adults in the United States are now expected to develop diabetes during their lifetime. More than 37 million people of all ages (about 11% of the United States population) have diabetes today. 96 million adults (more than one in three) have pre-diabetes, blood glucose levels that are higher than normal but not high enough to be classified as diabetes.

美国疾病控制与预防中心估计，约五分之二的美国成年人预计在一生中会患上糖尿病。目前，全美有超过3700万人（约占美国总人口的11%）患有糖尿病。此外，9600万成年人（超过三分之一）处于糖尿病前期，血糖水平高于正常值但尚未达到糖尿病的诊断标准。

Diabetes is also one of the largest economic burdens on the United States health care system with one dollar out of every four dollars in United States health care costs spent on caring for people with diabetes. Despite the current availability of many diabetes medications, there remains a significant need in the treatment and care of patients with diabetes..

糖尿病也是美国医疗系统最大的经济负担之一，美国医疗费用中每四美元就有一美元花在糖尿病患者的护理上。尽管目前有许多糖尿病药物可用，但在糖尿病患者的治疗和护理方面仍然存在显著的需求。

About Icovamenib

关于Icovamenib

Icovamenib is an investigational, orally bioavailable, potent, and selective covalent inhibitor of menin. The molecule was built using Biomea’s FUSION™ System and is designed to regenerate insulin-producing beta cells with the aim to cure diabetes. Icovamenib’s proposed mechanism of action in diabetes is to enable the proliferation, preservation, and reactivation of a patient’s own healthy, functional, insulin-producing beta cells.

Icovamenib 是一种研究性、口服生物可利用、强效且选择性的共价 menin 抑制剂。该分子是使用 Biomea 的 FUSION™ 系统构建的，旨在再生胰岛素生成的 β 细胞，以治愈糖尿病。Icovamenib 在糖尿病中的作用机制是促进患者自身健康、功能性胰岛素生成 β 细胞的增殖、保护和重新激活。

As the potentially first disease-modifying therapy for T1D and T2D, icovamenib could become an important addition and complement to the diabetes treatment landscape once it has successfully completed its ongoing clinical studies and received regulatory approval..

作为1型糖尿病和2型糖尿病潜在的首个疾病修饰疗法，伊科伐美尼布一旦成功完成正在进行的临床研究并获得监管批准，可能成为糖尿病治疗领域的重要的补充和助力。

About Biomea Fusion

关于Biomea Fusion

Biomea is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and metabolic disease. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response..

Biomea是一家临床阶段的糖尿病和肥胖症药物公司，专注于发现和开发口服共价小分子药物，以改善糖尿病、肥胖症和代谢疾病患者的生活。共价小分子是一种合成化合物，能够与其靶蛋白形成永久性结合，相比传统的非共价药物具有多种潜在优势，包括更高的靶标选择性、更低的药物暴露量以及能够引发更深层次、更持久的反应。

We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small-molecule medicines designed to maximize clinical benefit for patients. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure..

我们正在利用我们的专有FUSION™系统来发现、设计和开发一条下一代共价结合小分子药物的管线，旨在为患者最大化临床效益。我们力求对我们所服务患者的疾病治疗产生重大影响。我们的目标是实现治愈。

Visit us at biomeafusion.com and follow us on

访问我们的网站 biomeafusion.com 并关注我们

LinkedIn

领英

,

，

X

X

and

和

Facebook

脸书

.

。

Forward-Looking Statements

前瞻性声明

Statements we make in this press release may include statements which are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

本新闻稿中我们所做的声明可能包括并非历史事实的陈述，这些陈述根据经修订的《1933年证券法》第27A条（“证券法”）和经修订的《1934年证券交易法》第21E条（“交易法”）的规定被视为前瞻性陈述。

These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements.

这些声明可以通过诸如“目标”、“预期”、“相信”、“可能”、“估计”、“预计”、“预测”、“目的”、“打算”、“或许”、“计划”、“可能”、“潜力”、“寻求”、“将”等词语或这些词语的变体或类似表达来识别，这些词语旨在识别前瞻性声明。

Any such statements in this press release that are not statements of historical fact, including statements regarding the clinical and therapeutic potential of our product candidates and development programs, including BMF-219, the potential of BMF-219 as a treatment for T1D and T2D, our research, development and regulatory plans, the progress of our ongoing and planned clinical trials, including COVALENT-111, the availability of data from our clinical trials and the timing of such events, may be deemed to be forward-looking statements.

本新闻稿中的任何非历史事实的陈述，包括关于我们产品候选物和开发计划的临床及治疗潜力的陈述，包括BMF-219、BMF-219作为T1D和T2D治疗的潜力、我们的研究、开发和监管计划、我们正在进行和计划中的临床试验（包括COVALENT-111）的进展、我们临床试验数据的可用性以及此类事件的时间安排，均可能被视为前瞻性陈述。

We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions..

我们打算使这些前瞻性陈述受到《证券法》第27A条和《交易法》第21E条中关于前瞻性陈述的安全港条款的保护，并且我们作出此声明是为了遵守这些安全港条款。

Contact

联系

:

：

Meichiel Jennifer Weiss

米歇尔·詹妮弗·韦斯

Sr. Director, Investor Relations and Corporate Development

投资者关系和企业发展高级总监

IR@biomeafusion.com

IR@biomeafusion.com